A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

被引：0
作者：
Toshihiko Doi
Kohei Shitara
Takashi Kojima
Takayuki Yoshino
Aruna Dontabhaktuni
Hans Rebscher
Shande Tang
Jan Cosaert
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Department Gastrointestinal Oncology
[2] Eli Lilly and Company,undefined
[3] PharmaPro Consulting,undefined
[4] Inc,undefined
[5] Sotio,undefined
[6] National Cancer Center Hospital East,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
Cixutumumab; Solid tumor; Insulin receptor; Japanese;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1253 / 1262
页数：9
相关论文
共 282 条
[71]  
Gupta S(undefined)undefined undefined undefined undefined-undefined
[72]  
Lei X(undefined)undefined undefined undefined undefined-undefined
[73]  
Busaidy N(undefined)undefined undefined undefined undefined-undefined
[74]  
Hong D(undefined)undefined undefined undefined undefined-undefined
[75]  
Chen HX(undefined)undefined undefined undefined undefined-undefined
[76]  
Doyle LA(undefined)undefined undefined undefined undefined-undefined
[77]  
Heilbrun LK(undefined)undefined undefined undefined undefined-undefined
[78]  
Rohren E(undefined)undefined undefined undefined undefined-undefined
[79]  
Ng C(undefined)undefined undefined undefined undefined-undefined
[80]  
Chandhasin C(undefined)undefined undefined undefined undefined-undefined
3456789101112